Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.

Bhatia R, Khan I, Li X, Gautam S, Seshacharyulu P, Alsafwani ZW, Bhyravbhatla N, Ponnusamy MP, Jain M, Malafa M, Bindu S, Gulzar A, Nair H, Batra SK, Kumar S

Open source

DOI: 10.1038/s41698-025-01046-w
Published: 2025 Aug 22
Container: NPJ precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41698-025-01046-w,
  title = {Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.},
  author = {Bhatia R and Khan I and Li X and Gautam S and Seshacharyulu P and Alsafwani ZW and Bhyravbhatla N and Ponnusamy MP and Jain M and Malafa M and Bindu S and Gulzar A and Nair H and Batra SK and Kumar S},
  year = {2025},
  journal = {NPJ precision oncology},
  doi = {10.1038/s41698-025-01046-w},
  url = {https://doi.org/10.1038/s41698-025-01046-w}
}

RIS

TY  - JOUR
TI  - Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.
AU  - Bhatia R
AU  - Khan I
AU  - Li X
AU  - Gautam S
AU  - Seshacharyulu P
AU  - Alsafwani ZW
AU  - Bhyravbhatla N
AU  - Ponnusamy MP
AU  - Jain M
AU  - Malafa M
AU  - Bindu S
AU  - Gulzar A
AU  - Nair H
AU  - Batra SK
AU  - Kumar S
PY  - 2025
JO  - NPJ precision oncology
DO  - 10.1038/s41698-025-01046-w
UR  - https://doi.org/10.1038/s41698-025-01046-w
ER  -

APA

R, B., I, K., X, L., S, G., P, S., ZW, A., N, B., MP, P., M, J., M, M., S, B., A, G., H, N., SK, B., & S, K. (2025). Targeting cancer-associated fibroblast-driven LIF/LIFR axis improves the therapeutic efficacy of gemcitabine and nab-paclitaxel in pancreatic cancer.. NPJ precision oncology. https://doi.org/10.1038/s41698-025-01046-w

Source records

pubmed · retrieved 2026-09-27T11:51:57.426Z